Richard Zeifman is a Ph.D. student in Clinical Psychology at Ryerson University. He completed an M.A. in Clinical Psychology at Ryerson University in 2017 and is currently a research intern in the IMPACT Lab (Ryerson University), Remedy, and the Centre for Psychedelic Research (Imperial College London). He has received funding awards (totalling $164,000), including four years of funding from the Canadian Institutes of Health Research. Richard has presented his research 39 times (15 first author) at academic conferences, and has co-authored one book chapter and 16 (9 first author) peer-reviewed journal articles.
Richard’s research focuses on enhancing evidence-based psychotherapeutic interventions by (a) examining the mechanisms through which psychotherapy leads to change and (b) integrating evidence-based psychotherapies with novel pharmacological interventions (e.g., psilocybin, MDMA).
Currently, his primary focus is on identifying transdiagnostic mechanisms of change through which psychedelic-assisted therapies lead to positive therapeutic outcomes. Richard is also contributing toward research programs including MDMA-augmented cognitive processing therapy and cognitive behavioural conjoint therapy for individuals with posttraumatic stress disorder (PTSD).
Richard’s clinical training includes completing several clinical practicums, where he has focused on conducting psychological assessments and providing evidence-based (individual and group) treatment, including cognitive behavioural therapies and emotion-focused therapy, for individuals with a range of clinical presentations (e.g., PTSD, anxiety disorders, depressive disorders, borderline personality disorder). He is currently conducting assessments and trauma-focused treatment for individuals with PTSD and their close others.